Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases
Top Cited Papers
Open Access
- 12 March 2020
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Central Science
- Vol. 6 (3), 315-331
- https://doi.org/10.1021/acscentsci.0c00272
Abstract
No abstract availableKeywords
This publication has 47 references indexed in Scilit:
- Small molecule inhibitors of the SARS-CoV Nsp15 endoribonucleaseVirus Adaptation and Treatment, 2010
- Differential Downregulation of ACE2 by the Spike Proteins of Severe Acute Respiratory Syndrome Coronavirus and Human Coronavirus NL63Journal of Virology, 2010
- The spike protein of SARS-CoV — a target for vaccine and therapeutic developmentNature Reviews Microbiology, 2009
- Crystal Structures of the Main Peptidase from the SARS Coronavirus Inhibited by a Substrate-like Aza-peptide EpoxideJournal of Molecular Biology, 2005
- Structure of SARS Coronavirus Spike Receptor-Binding Domain Complexed with ReceptorScience, 2005
- DC-SIGN and DC-SIGNR Interact with the Glycoprotein of Marburg Virus and the S Protein of Severe Acute Respiratory Syndrome CoronavirusJournal of Virology, 2004
- pH-Dependent Entry of Severe Acute Respiratory Syndrome Coronavirus Is Mediated by the Spike Glycoprotein and Enhanced by Dendritic Cell Transfer through DC-SIGNJournal of Virology, 2004
- Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patientsJournal of Antimicrobial Chemotherapy, 2003
- Coronavirus Main Proteinase (3CL pro ) Structure: Basis for Design of Anti-SARS DrugsScience, 2003
- A Human Homolog of Angiotensin-converting EnzymeJournal of Biological Chemistry, 2000